Drug Profile

Entrectinib companion diagnostic - Thermo Fisher Scientific

Latest Information Update: 17 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Sep 2021 Registered for Non-small cell lung cancer (Diagnosis) in Japan (unspecified route) prior to September 2021
08 Jul 2020 Thermo Fisher Scientific and Chugai Pharmaceutical enter into an agreement for an Oncomine Dx Target Test to identify patients with Non-small cell lung cancer that may benefit from entrectinib treatment, in Japan
08 Jul 2020 Preregistration in Non-small cell lung cancer (Diagnosis) in Japan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com